Thoracoscopic Intradiscal Spine Fusion Using a Minimally Invasive Gene-Therapy Technique

Riew, K. Daniel; Lou, Jueren; Wright, Neill M.; Cheng, Su‐Li; Bae, Kyongtae T.; Avioli, Louis V.

doi:10.2106/00004623-200305000-00014

Cited by 44 publications

(19 citation statements)

References 16 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Together with studies from other research groups using adenovirus, retrovirus and nonviral vectors [Mason et al, 1998;Lieberman et al, 1999;Baltzer et al, 2000;Okubo et al, 2000;Laurencin et al, 2001;Riew et al, 2003], they provide strong evidence for the feasibility of this approach as a clinical alternative to BMP protein therapy. In related studies, one of us (RBR) showed that AdCMV-BMP7 transduction of tooth pulp can stimulate regeneration of a dentin-like mineralized matrix in vivo [Rutherford, 2001].…”

Section: Use Of Adcmv-bmp7 For Regeneration Of Cranial and Long Bone mentioning

confidence: 81%

Gene Therapy Approaches for Bone Regeneration

Franceschi

Yang

Rutherford

et al. 2004

Cells Tissues Organs

View full text Add to dashboard Cite

Gene therapy represents a promising approach for delivering regenerative molecules to specific tissues including bone. Several laboratories have shown that virus-based BMP expression vectors can stimulate osteoblast differentiation and bone formation in vivo. Both in vivo and ex vivo transduction of cells can induce bone formation at ectopic and orthotopic sites. Adenovirus and direct DNA delivery of genes encoding regenerative molecules can heal critical-sized defects of cranial and long bones. Although osteogenic activity can be demonstrated for individual BMP vectors, substantial synergies may be achieved using combinatorial gene therapy to express complimentary osteogenic signals including specific combinations of BMPs or BMPs and transcription factors. Further control of the bone regeneration process may also be achieved through the use of inducible promoters that can be used to control the timing and magnitude of expression for a particular gene. Using these types of approaches, it should be possible to mimic natural processes of bone development and fracture repair and, in so doing, be able to precisely control both the amount and type of bone regenerated.

show abstract

Section: Use Of Adcmv-bmp7 For Regeneration Of Cranial and Long Bone mentioning

confidence: 81%

Gene Therapy Approaches for Bone Regeneration

Franceschi

Yang

Rutherford

et al. 2004

Cells Tissues Organs

View full text Add to dashboard Cite

show abstract

“…Cells were then incubated overnight with AdBMP-2. Anterior arthrodesis was performed by a thoracoscopic technique and the researchers reported a 100% fusion rate by histologic and radiologic evaluation for six of six disc spaces treated with AdBMP-2, whereas none of the controls fused (Riew et al, 2003). Wang et al compared single-level posterolateral spine fusion rates between rhBMP-2 with various carriers, bone marrow cells transduced for 48 hours with AdBMP-2 and iliac crest bone graft (ICBG) in rats.…”

Section: Cells Combined With Ex Vivo Gene Therapymentioning

confidence: 99%

Ex Vivo Gene Therapy for Spinal Fusion

Kaito¹,

Ngo²,

Wang³

2011

Gene Therapy Applications

View full text Add to dashboard Cite

“…BMP-2, approved by Food and Drug Administration (FDA) for clinical practice, is the most potent member in promoting bone and cartilage development and therefore wins a popular choice for MSCs-based BTE (Lieberman et al, 1998;Lieberman et al, 1999;Lou et al, 1999;Turgeman et al, 2001;Olmsted-Davis et al, 2002;Blum et al, 2003;Gugala et al, 2003;Park et al, 2003;Riew et al, 2003;Tsuda et al, 2003;Kumar et al, 2004;Hasharoni et al, 2005;Egermann et al, 2006;Feeley et al, 2006). The BMP-2-modified MSCs are proven to increase the alkaline phosphatase (ALP) activity, mineralization, and cell proliferation in vitro and induce ectopic bone formation, heal critical size bone defect, repair fracture, and trigger spinal fusion in vivo (Lou et al, 1999;Moutsatsos et al, 2001;Turgeman et al, 2001;Blum et al, 2003;Park et al, 2003;Riew et al, 2003;Tsuda et al, 2003;Hasharoni et al, 2005;Egermann et al, 2006;Feeley et al, 2006). BMP-7 plays a key role in osteoblast differentiation, and there is only one study in which MSCs are engineered with BMP-7.…”

Section: Applicable Genes For Mscs Modificationmentioning

confidence: 99%

“…Adenovirus vector is one of the most popular vectors for MSC gene therapy aimed at BTE Dumont et al, 2002;Olmsted-Davis et al, 2002;Blum et al, 2003;Dayoub et al, 2003;Gugala et al, 2003;Li et al, 2003;Park et al, 2003;Riew et al, 2003;Sugiyama et al, 2003;Tsuda et al, 2003;Yang et al, 2003;Kumar et al, 2004;Zheng et al, 2004;Zhao et al, 2005;Egermann et al, 2006;Feeley et al, 2006;Zachos et al, 2006). Adenovirus vector is characterized by efficient transduction of quiescent cells and a relatively high capacity for transgene insertion.…”

Section: Selection Of Vectorsmentioning

confidence: 99%

Genetically Engineered Mesenchymal Stem Cells: The Ongoing Research for Bone Tissue Engineering

Hong

Chen²,

et al. 2010

The Anatomical Record

View full text Add to dashboard Cite

Bone grafting is crucial in the surgical treatment of bone defects and nonunion fractures. Autogenous bone, allogenous bone, and biomaterial scaffold are three main sources of bone grafts. The biomaterial scaffold, both natural and synthetic, is widely accessible but weak in osteogenic potential. One approach to solve this problem is cell-based bone tissue engineering (BTE), established by growing living osteogenic cells on scaffold in vitro to build up its osteoinducitive capability. Mesenchymal stem cell (MSC) is suitable for use in cell-based BTE, but it remains a considerable challenge to induce MSCs to form solely bone and while preventing MSCs from differentiating into fats, muscles, and possibly neural elements in vivo. Recently, there is a drastic rise in use of genetically engineered MSCs, which can secrete growth factors or alter the transcription level, leading to osteoblast lineage commitment, bone formation, fracture repair, and spinal fusion. In this article, we reviewed the literatures regarding applications of genetically engineered MSCs in BTE. We addressed the currently applicable genes and candidate genes for MSCs modification, transduction efficiency and safety issues of the transfect vectors, and administration routes, and we briefly described in vivo tracking and potential clinical application of the genetically modified MSCs in BTE. Anat Rec, 293:531-537, 2010. V V C 2009 Wiley-Liss, Inc.

show abstract

Thoracoscopic Intradiscal Spine Fusion Using a Minimally Invasive Gene-Therapy Technique

Abstract: Kyongtae T.; and Avioli, Louis V., ,"Thoracoscopic intradiscal spine fusion using a minimally invasive gene-therapy technique

Cited by 44 publications

References 16 publications

Gene Therapy Approaches for Bone Regeneration

Gene Therapy Approaches for Bone Regeneration

Ex Vivo Gene Therapy for Spinal Fusion

Genetically Engineered Mesenchymal Stem Cells: The Ongoing Research for Bone Tissue Engineering

Contact Info

Product

Resources

About